Science and Health News

Researchers have engineered a low-cost plastic material that could become the basis for clothing that cools the wearer, reducing the need for energy-consuming air conditioning.

The U. S. Food and Drug Administration today issued a final rule establishing that over-the-counter (OTC) consumer antiseptic wash products containing certain active ingredients can no longer be marketed.

Cell lines are cultured cells that are commonly used in medical research. New results from Uppsala University show that such cells are not always what they are assumed to be. Using genetic analyses, the researchers showed that a commonly used cell line which was established in Uppsala almost fifty years ago does not originate from the patient it is claimed to stem from. The findings are published today in the journal Science Translational Medicine.

University of Michigan researchers have successfully demonstrated a new technique that combines laser light with an FDA-approved fluorescent dye to monitor cell structure and activity at the molecular level.

Tasmanian devils are evolving in response to a highly lethal and contagious form of cancer, a Washington State University researcher has found.

Scientists at the Laboratory for Neuroprotection run by the RASA Center at the Tomsk Polytechnic University (TPU) in partnership with colleagues from the Center for Cardiovascular Research and the Department of Cardiology, Massachusetts General Hospital (Harvard Medical School, U.S.) are looking into a new compound that is believed to be able to protect the human brain against ischemic stroke. Researchers from the University of Montana and colleagues from other Russian universities are also participating, the TPU website announced.

IBM scientists will collaborate with the Icahn School of Medicine at Mount Sinai to test on prostate cancer

Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer's disease. These protein deposits in the brain are a classic sign of Alzheimer's disease and contribute to the progressive degeneration of brain cells. The researchers furthermore demonstrated in an early stage clinical study that, after one year of treatment with Aducanumab, cognitive decline could be significantly slowed in antibody-treated patients as opposed to the placebo group.